18F-FDG PET及PET/CT在外阴癌中的应用:系统评价与荟萃分析
该系统评价与荟萃分析纳入10篇文献,其中7篇评估术前18F-FDG PET/CT对外阴癌淋巴结分期的诊断效能。按患者分析(72例)汇总敏感度0.70、特异度0.90;按腹股沟分析(245个)汇总敏感度0.76、特异度0.88。结论认为术前阴性PET/CT可能排除早期外阴癌腹股沟转移,阳性结果需谨慎解读。
要点
- 术前阴性PET/CT可能排除早期外阴癌腹股沟转移。
- 阳性PET/CT结果应谨慎解读,避免过度诊断。
- 证据限于少量回顾性研究,需更大前瞻性研究验证。
核心结论
- 尽管文献数据有限,术前阴性PET/CT可能排除早期外阴癌患者的腹股沟转移,并筛选适合微创手术者。
- 阳性PET/CT结果应谨慎解读。
- 需更大前瞻性研究确认结果并评估标准化半定量分析的诊断价值。
研究设计与样本
- 系统评价与荟萃分析,检索PubMed/Medline和Embase数据库。
- 共纳入10篇文章,其中7篇评估术前18F-FDG PET/CT对淋巴结分期的诊断效能。
- 对纳入文章进行方法学质量评估。
- 计算按患者和按腹股沟的汇总敏感度、特异度、阳性预测值、阴性预测值及诊断比值比,并给出95%CI。
主要发现
- 按患者定性分析(4项研究,72例)汇总敏感度0.70(95%CI 0.44-0.95)、特异度0.90(95%CI 0.76-1.04)、阳性预测值0.86(95%CI 0.66-1.06)、阴性预测值0.77(95%CI 0.56-0.97)、诊断比值比10.49(95%CI 1.68-65.50)。
- 按腹股沟定性分析(5项研究,245个腹股沟)汇总敏感度0.76(95%CI 0.57-0.94)、特异度0.88(95%CI 0.82-0.94)、阳性预测值0.70(95%CI 0.55-0.85)、阴性预测值0.92(95%CI 0.86-0.97)、诊断比值比19.43(95%CI 6.40-58.95)。
临床怎么用
- 对当前不适合前哨淋巴结活检的早期外阴癌患者,术前阴性PET/CT可能有助于排除腹股沟转移。
- 阴性PET/CT可辅助筛选适合 less invasive 手术治疗的患者。
- 阳性PET/CT结果应结合临床谨慎解读,避免仅凭阳性结果做出治疗决策。
局限性
- 文献数据有限。
- 纳入研究数量少(共10篇,诊断效能分析仅7篇)。
- 需更大前瞻性研究确认结果。
- 未评估标准化半定量分析与定性分析的诊断价值比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIM: The aims of this study were to determine the role of 18F-FDG PET/CT in vulvar cancer patients and to extract summary estimates of its diagnostic performance for preoperative lymph node staging. PATIENTS AND METHODS: PubMed/Medline and Embase databases were searched to identify studies evaluating 18F-FDG PET/CT in vulvar cancer patients. The assessment of methodological quality of the included articles was performed. Per-patient and per-groin pooled estimates, with 95% confidence intervals (CIs), of sensitivity, specificity, positive predictive value (PPV), negative predictive value (NPV), and diagnostic odds ratio (DOR) were calculated. RESULTS: Ten articles were included in the systematic review, 7 among which evaluated the diagnostic performance of preoperative 18F-FDG PET/CT for lymph node staging. Qualitative per-patient analysis (72 patients from 4 studies) resulted in estimated pooled sensitivity, specificity, PPV, NPV, and DOR of 0.70 (95% CI, 0.44-0.95), 0.90 (95% CI, 0.76-1.04), 0.86 (95% CI, 0.66-1.06), 0.77 (95% CI, 0.56-0.97), and 10.49 (95% CI, 1.68-65.50), respectively. Qualitative per-groin analysis (245 groins from 5 studies) resulted in estimated pooled sensitivity, specificity, PPV, NPV, and DOR of 0.76 (95% CI, 0.57-0.94), 0.88 (95% CI, 0.82-0.94), 0.70 (95% CI, 0.55-0.85), 0.92 (95% CI, 0.86-0.97), and 19.43 (95% CI, 6.40-58.95), respectively. CONCLUSIONS: Despite limited literature data, this systematic review and meta-analysis revealed that a negative preoperative PET/CT scan may exclude groin metastases in at least early-stage vulvar cancer patients currently unfit for sentinel node biopsy and select those eligible for a less invasive surgical treatment. A positive PET/CT result should otherwise be interpreted with caution. Larger prospective studies are needed to confirm these results and to evaluate the diagnostic value of standardized semiquantitative analysis compared with the qualitative one.
引用
- Triumbari EKA, de Koster EJ, Rufini V, et al. 18F-FDG PET and 18F-FDG PET/CT in Vulvar Cancer: A Systematic Review and Meta-analysis. Clin Nucl Med. 2021. PMID: 33234921. doi:10.1097/RLU.0000000000003411
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。